NMTC vs. INFU, LAKE, PTHL, LUCD, LUNG, OBIO, ICAD, MGRM, ZJYL, and FONR
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include InfuSystem (INFU), Lakeland Industries (LAKE), Pheton (PTHL), Lucid Diagnostics (LUCD), Pulmonx (LUNG), Orchestra BioMed (OBIO), icad (ICAD), Monogram Orthopaedics (MGRM), Jin Medical International (ZJYL), and Fonar (FONR). These companies are all part of the "medical equipment" industry.
NeuroOne Medical Technologies vs. Its Competitors
NeuroOne Medical Technologies (NASDAQ:NMTC) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.
NeuroOne Medical Technologies has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 8.9% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 11.4% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, NeuroOne Medical Technologies' average media sentiment score of 0.00 equaled InfuSystem'saverage media sentiment score.
NeuroOne Medical Technologies currently has a consensus target price of $1.45, suggesting a potential upside of 102.80%. InfuSystem has a consensus target price of $13.00, suggesting a potential upside of 111.04%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than NeuroOne Medical Technologies.
InfuSystem has a net margin of 1.12% compared to NeuroOne Medical Technologies' net margin of -75.41%. InfuSystem's return on equity of 2.78% beat NeuroOne Medical Technologies' return on equity.
InfuSystem has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
Summary
InfuSystem beats NeuroOne Medical Technologies on 13 of the 15 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:NMTC) was last updated on 7/3/2025 by MarketBeat.com Staff
Free NMTC Stock Alerts